Glaukos jumps as Citi raises target to $135 ahead of ASCRS Epioxa spotlight
Glaukos shares jumped as a major Wall Street firm lifted its price target to $135 from $125 while reiterating a Buy rating. Momentum was also supported by rising attention ahead of ASCRS 2026 (April 10–13 in Washington, D.C.), where Glaukos plans prominent Epioxa-focused sessions.
1. What’s moving the stock
Glaukos (GKOS) is trading higher today after Citi raised its price target to $135 from $125 and reiterated a Buy rating, giving investors a fresh valuation anchor above the prior target and fueling incremental demand for the shares. (tipranks.com)
2. Why the timing matters this week
The analyst-driven move is landing just ahead of ASCRS 2026 (April 10–13, 2026, Washington, D.C.), where Glaukos is scheduled to be featured across multiple scientific sessions and plans an educational symposium introducing Epioxa, its FDA-approved epi-on, oxygen-enriched corneal cross-linking therapy for keratoconus. A higher-profile conference window can amplify investor focus on near-term commercialization narratives and physician adoption signals. (eyewire.news)
3. What investors are watching next
Near term, traders will look for any incremental updates around Epioxa launch execution and early demand indicators, as the company has positioned Epioxa for commercial availability and launch activities in early 2026. Conference commentary, new training/site-of-care updates, or reimbursement/access progress could determine whether today’s rally holds or fades. (investors.glaukos.com)